Oral Activated Articles & Analysis
20 news found
About OCEANIC-AF and OCEANIC-STROKE OCEANIC-AF is a multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, two-arm Phase III study investigating asundexian compared to apixaban (a non-vitamin K antagonist oral anticoagulant) in patients with atrial fibrillation at risk for stroke to determine the safety ...
ByBayer AG
Stimulate the epidermis through HIFU ultrasonic beauty equipment, combined with oral ACME-TE-A generating too, two-way combined anti-aging physiotherapy process, clinical verification, after the patient undergoes HIFU ultrasonic treatment, facial wrinkles, sagging, enlarged pores, and skin luster are uniform There are varying degrees of improvement. ...
” Of the multitude of medications available for the more than 17 million child, adolescent, and adult patients in the U.S. living with ADHD, no currently available medications offer a single oral dose that provides patients entire active-day efficacy. This Phase 3 trial is being conducted in an Adult Laboratory Setting (ALS) which has been used extensively ...
Under its subsidiary, OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immune activator for the treatment of aggressive forms of prostate cancer. ...
(Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the first 13 patients have been dosed in Part 1 of the pivotal Phase 3 SERENITY III trial investigating at-home use of BXCL501 (dexmedetomidine) sublingual film, the Company’s proprietary, ...
Abstract Project Summary Abstract The epidemic of cardiovascular diseaseCVDis a global phenomenon that remains the number one cause of death throughout the worldkilling nearlymillion people per yeara number that is expected to grow tomillion byA high cholesterol level is well known risk factors for heart diseaseAlthough blood cholesterol can be lowered using a number of marketed drugsof which ...
Under its subsidiary OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint ...
Under its subsidiary, OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint ...
The Virusight solution demonstrated an overall sensitivity of 92.7% (positive percent agreement) and specificity of 96.8% (negative percent agreement) as compared to an EC marked RT-PCR and was shown to be a safe and reliable test for the detection of SARS-CoV-2 antigens and/or virus particles in oral swab samples, providing diagnosis of active COVID-19, ...
Based on these findings, LUM-201, an oral growth hormone secretagogue, could prove to be an efficacious therapeutic for those suffering from this chronic liver ...
(Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the first patient has been dosed in the Phase 3 TRANQUILITY II study of BXCL501, the Company’s proprietary, orally dissolving thin film formulation of dexmedetomidine, for the acute ...
OnkosXcel plans to progress the development of BXCL701, an investigational orally administered innate immune activator designed to initiate inflammation in the tumor microenvironment. ...
The abstract is available here. PAD4 activity in tumor cells may play a significant role in cancer metastasis. ...
Because IGALMI decreases sympathetic nervous system activity, hypotension and/or bradycardia may be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension, and in geriatric patients. ...
VAXIMM retains rights to its first-in-class oral T-cell activation platform technology and all other product candidates, including VXM01, which is being developed for the treatment of glioblastoma. ...
POSTER PRESENTATION DETAILS Title: BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype—Phase 2a results. ...
Study demonstrated a favorable risk/benefit profile over a three-year period, with safety comparable to AURORA 1, and sustained efficacy - Topline results show sustained meaningful reductions in proteinuria compared to mycophenolate mofetil (MMF) and low-dose oral corticosteroids alone, the active study control - Similar to the active ...
The teams will collaborate to accelerate the development of cytoTIL, including process and analytical development and clinical readiness activities. “TIL therapy has emerged as a promising option for treating patients with solid tumors, though its widespread use today is limited by safety and efficacy challenges,” said Rodabe Amaria, M.D., associate professor of ...
OMIT enables regular administration of allergy immunotherapy to desensitize a patient to allergies while a user brushes their teeth. By coupling a daily oral care activity with allergy immunotherapy, OMIT, delivered using Allerdent®, can help address the issues associated with poor adherence that limits the use and effectiveness of other forms of allergy ...
CHICAGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Shifa Biomedical Corporation (Shifa), a drug discovery biopharmaceutical company focused on developing novel agents to treat cardiovascular disease and hypercholesteremia, today announced exciting preclinical data involving the company’s pre-clinical candidate, P-21, which interferes with the interaction between PCSK9 and the LDL receptor (LDLR). ...